Japan okays Fujifilm's Ebola drug

The photographic giant's stock rises as it becomes the leading contender to develop a large scale Ebola treatment

by Adam Gale
Last Updated: 17 Oct 2014

An anti-flu drug developed by Fujifilm, a Japanese conglomerate better known for its cameras, may just have become the leading contender in the race to find a viable treatment for Ebola. Japan’s health ministry approved the company’s drug Favipiravir for use in treating Ebola patients yesterday, causing shares to rise 5.3% to ¥3,244 (£18.85).

The drug, which has the market name Avigan, was developed by Fujifilm’s subsidiary Toyama Chemical Co to fight flu, but has possible applications for Ebola treatment too.
Japan's thumbs up puts Favipiravir in pole position to be the first drug used in widescale treatment of the West and Central African Ebola outbreak, which has so far killed up to 1,400 people.
Unlike US-based Mapp Pharmaceutical’s Zmapp, supplies of which have been effectively exhausted treating six patients (two of whom have died), Favipiravir has been produced in large quantities since March, when Japan began stockpiling it against flu epidemics.
The drug works by inhibiting gene replication in infected cells, and comes in the form of a pill. ‘Since Ebola and influenza viruses are the same type,’ said Fujifilm spokesman Takao Aoki. 'Theoretically, the same effects can be expected on Ebola.’
Japanese Chief Cabinet Secretary Yoshihide Suga said the company’s Favipiravir stock of 20,000 could be made available whenever the WHO or medical officials in affected countries request it. Fujifilm and its US partner MediVector are in talks with the US Food and Drug Administration about fast-tracking clinical trials.

There are other companies searching for an Ebola cure, but it's only became any kind of urgent due to the media coverage around the latest outbreak. Sadly, there isn't much money to be made in treating diseases that affect relatively small numbers of poor people.

Find this article useful?

Get more great articles like this in your inbox every lunchtime

How to use workplace conflict to your advantage

But beware the festering feud.

Efficient chickens, less stuff, more optimism: The real way to address climate change ...

What is dematerialisation, and why does it matter?

The 5 behaviours of charismatic leaders

How to become more inspirational (without having a personality transplant).

When should you step down as CEO?

Bob Iger's departure poses an unpopular question for bosses.

The death and resurrection of the premium customer

Top-end service is no longer at the discretion of the management.

What HS2 can teach you about project failure

And how you can prevent projects going astray.